A time study comparing the appearance of catabolites of 9 alpha, 11 alpha, 15(S)-trihydroxyprosta-5,13-dienoic acid in blood and urine during constant intravenous infusion of tritiated 9 alpha, 11 alpha, 15(S)-trihydroxyprosta-5,13-dienoic acid in the rat. Isolation of a new circulating catabolite.
Profiles of 9 alpha, 11 alpha, 15(S)-trihydroxyprosta-5,13-dienoic acid (PGF2 alpha) and its catabolites in blood and urine of male adult Wistar rats were determined by high pressure liquid chromatography during and after slow intravenous infusion of tritium-labeled PGF2 alpha. In addition to PGF2 alpha and 15-keto-13,14-dihydro-PGF2 alpha, a major catabolite in blood during the infusion was identified as tetranor-15-keto-13,14-dihyro-PGF2 alpha (VII). This product was absent in the corresponding urine samples. VII was still detected in blood 2 h after the infusion was terminated. VII was previously shown by us to be an intermediate in the formation of certain urinary products of PGF2 alpha. These other catabolites of PGF2 alpha were also observed in both blood and urine although their levels were greater in the urine. Our observations indicate that a long lasting catabolite of PGF2 alpha, i.e. VII, as well as all the urinary catabolites of PGF2 alpha appear in the circulation. These results suggest that these catabolites are mostly (although not exclusively) extrarenal in origin (probably all hepatic) entering the circulation prior to their excretion by the kidney.